ATE437889T1 - Chemokin-mucin fusionsproteine mit einer gpi- ankerdomäne und deren verwendung als tumor-immun- adjuvanzien oder in der geweberegeneration - Google Patents

Chemokin-mucin fusionsproteine mit einer gpi- ankerdomäne und deren verwendung als tumor-immun- adjuvanzien oder in der geweberegeneration

Info

Publication number
ATE437889T1
ATE437889T1 AT05026397T AT05026397T ATE437889T1 AT E437889 T1 ATE437889 T1 AT E437889T1 AT 05026397 T AT05026397 T AT 05026397T AT 05026397 T AT05026397 T AT 05026397T AT E437889 T1 ATE437889 T1 AT E437889T1
Authority
AT
Austria
Prior art keywords
gpi
cells
tissue regeneration
tumour
chemokine
Prior art date
Application number
AT05026397T
Other languages
English (en)
Inventor
Ralf Prof Dr Huss
Peter Nelson
Hermann-Josef Prof Dr Groene
Original Assignee
Apceth Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apceth Gmbh & Co Kg filed Critical Apceth Gmbh & Co Kg
Application granted granted Critical
Publication of ATE437889T1 publication Critical patent/ATE437889T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/524—Thrombopoietin, i.e. C-MPL ligand
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4727—Mucins, e.g. human intestinal mucin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT05026397T 2005-12-02 2005-12-02 Chemokin-mucin fusionsproteine mit einer gpi- ankerdomäne und deren verwendung als tumor-immun- adjuvanzien oder in der geweberegeneration ATE437889T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05026397A EP1792914B1 (de) 2005-12-02 2005-12-02 Chemokin-Mucin Fusionsproteine mit einer GPI-Ankerdomäne und deren Verwendung als Tumor-Immun-Adjuvanzien oder in der Geweberegeneration

Publications (1)

Publication Number Publication Date
ATE437889T1 true ATE437889T1 (de) 2009-08-15

Family

ID=36047948

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05026397T ATE437889T1 (de) 2005-12-02 2005-12-02 Chemokin-mucin fusionsproteine mit einer gpi- ankerdomäne und deren verwendung als tumor-immun- adjuvanzien oder in der geweberegeneration

Country Status (7)

Country Link
US (1) US20120208769A1 (de)
EP (1) EP1792914B1 (de)
AT (1) ATE437889T1 (de)
AU (1) AU2006319440B2 (de)
CA (1) CA2631587C (de)
DE (1) DE602005015733D1 (de)
WO (1) WO2007062844A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009014382A2 (en) * 2007-07-23 2009-01-29 Postech Academy-Industry Foundation Cxcl11 adjuvant compositions and uses thereof
CN102221608A (zh) * 2011-04-06 2011-10-19 浙江大学医学院附属第一医院 一种抗体组合物及其应用
US9296801B2 (en) * 2012-06-08 2016-03-29 Alkermes, Inc. Fusion polypeptides comprising mucin-domain polypeptide linkers
US10829771B2 (en) 2014-11-10 2020-11-10 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for expressing polypeptides on the surface of cells
DK3302527T3 (da) 2015-06-03 2020-03-30 Medical College Wisconsin Inc Manipuleret CCL20-låst-dimerpolypeptid
US11571462B2 (en) 2015-06-03 2023-02-07 The Medical College Of Wisconsin, Inc. Engineered CCL20 locked dimer polypeptide
CN113613727A (zh) * 2019-01-11 2021-11-05 嘉立医疗科技(广州)有限公司 多特异性前趋化因子治疗蛋白（park）及其制备和使用方法
CN114651002B (zh) * 2019-11-07 2024-12-13 武汉华大吉诺因生物科技有限公司 肿瘤特异性多肽序列及其应用
JP7787812B2 (ja) 2019-11-25 2025-12-17 アルカームス インコーポレーテッド 置換大環状化合物および関連する治療方法
US11760747B2 (en) 2020-12-21 2023-09-19 Alkermes, Inc. Substituted piperidino compounds and related methods of treatment
KR20230160294A (ko) 2021-03-24 2023-11-23 알케르메스, 인코포레이티드 Upar 항체 및 이를 갖는 융합 단백질

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2903999A (en) * 1998-03-12 1999-09-27 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Methods and compositions of chemokine-tumor antigen fusion proteins as cancer vaccines
AU2002329858A1 (en) * 2001-08-27 2003-03-10 Greenville Hospital System Gpi-anchored cytokines
EP1943332A4 (de) * 2005-10-14 2011-04-13 Medimmune Inc Zellpräsentation von antikörperbibliotheken

Also Published As

Publication number Publication date
DE602005015733D1 (de) 2009-09-10
EP1792914B1 (de) 2009-07-29
WO2007062844A1 (en) 2007-06-07
CA2631587C (en) 2013-01-15
AU2006319440B2 (en) 2012-02-09
AU2006319440A1 (en) 2007-06-07
EP1792914A1 (de) 2007-06-06
US20120208769A1 (en) 2012-08-16
CA2631587A1 (en) 2007-06-07

Similar Documents

Publication Publication Date Title
ATE437889T1 (de) Chemokin-mucin fusionsproteine mit einer gpi- ankerdomäne und deren verwendung als tumor-immun- adjuvanzien oder in der geweberegeneration
Overwijk et al. Engineering IL-2 to give new life to T cell immunotherapy
Persano et al. Anti-angiogenic gene therapy of cancer: current status and future prospects
AU2017219415B2 (en) Combination immune therapy and cytokine control therapy for cancer treatment
Schwager et al. The immunocytokine L19–IL2 eradicates cancer when used in combination with CTLA-4 blockade or with L19-TNF
JP2023175799A (ja) がんの免疫療法のためのｎｋｇ２ｄ－ｉｇ融合タンパク質
CN100457189C (zh) 细胞因子与肿瘤靶向蛋白的融合物
ES2438965T3 (es) Composiciones y métodos para administrar células madre
PE20121643A1 (es) Polipeptidos del factor ix modificados y usos de los mismos
WO2006047603A3 (en) Ungulates with genetically modified immune systems
AR065289A1 (es) Antagonistas de activina - actriia y sus usos para la promocion del crecimiento oseo y el tratamiento de mieloma multiple
BR112012009973A2 (pt) promotor de regeneração de tecido usando recrutamento de células-tronco mesenquimais da medula óssea e/ou células-tronco pluripotentes em sangue
CY1117115T1 (el) Καινοτομος ανοσοθεραπεια εναντι ογκων και νευρωνων του εγκεφαλου
BR112018007982A2 (pt) composição, reação enzimática e método para preparar um copolímero de enxerto
AR073078A1 (es) Construcciones flt (vegf- factor de crecimiento del endotelio vascular) solubles para el tratamiento del cancer.
CY1117695T1 (el) Υψηλης συγγενειας ανθρωπινα αντισωματα κατα της ανθρωπινης αγγειοποιητινης-2
AR073829A1 (es) Variantes de inmunoglobulinas y sus usos.
PE20211266A1 (es) Metodos y composiciones para la dosificacion de celulas t con receptor de antigeno quimerico alogenicas
PE20081841A1 (es) Composiciones farmaceuticas con capacidad de induccion de apotosis en celulas tumorales, utiles para el diagnostico y tratamiento de la leucemia linfocitica cronica b
Weisdorf The role of second transplants for leukemia
PE20200602A1 (es) Compuesto macrociclico y sus usos
Murer et al. Targeted delivery of TNF potentiates the antibody-dependent cell-mediated cytotoxicity of an anti-melanoma immunoglobulin
ATE527998T1 (de) Illudin-analoga als krebsmittel
CO2025013357A2 (es) Conjugados de ligando-fármaco citotóxico y usos farmacéuticos de estos
Park et al. Induction of vascular leak syndrome by tumor necrosis factor-alpha alone

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties